TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18803554

Group type: EXPERIMENTAL
Intervention: 0.1 mg rhTSH
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.005 mg rhTSH
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17134956

Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy (10mg daily) with a low-fat diet
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-fat diet only
Number of subjects: 71
Study: 14872456

Group type: EXPERIMENTAL
Intervention: Strength training (experimental group [EG])
Number of subjects: 70

Group type: COMPARATOR
Intervention: Range-of-motion exercises (control group [CG])
Number of subjects: 70
Study: 11692298

Group type: EXPERIMENTAL
Intervention: Intranasal zinc gluconate
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 9152291

Group type: EXPERIMENTAL
Intervention: Manganese-superoxide dismutase (Mn-SOD) activities in peripheral blood mononuclear cells
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mn-SOD messenger RNA expression
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transcriptional activation of Mn-SOD gene in glomerular endothelial cells exposed to 5% serum
Number of subjects: 12
Study: 7525233

Group type: EXPERIMENTAL
Intervention: Memorization of spatial location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressing a button for target location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counting stimuli in target location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive viewing
Number of subjects: 0
Study: 3046813

Group type: EXPERIMENTAL
Intervention: Postural manipulation to maximize QH (phase 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postural manipulation to minimize QH (phase 1)
Number of subjects: 0
Study: 31078831

Group type: EXPERIMENTAL
Intervention: Probiotic supplements (Winclove's Ecologic® Barrier), consumed daily over eight weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo, consumed daily over eight weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-depressed group (n = 20)
Number of subjects: 71
Study: 28692905

Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control dim-red light
Number of subjects: 78
Study: 25052347

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) monitoring after stopping TNFα-blocking therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Normal fecal calprotectin concentrations during follow-up
Number of subjects: 49
Study: 24059585

Group type: EXPERIMENTAL
Intervention: Follicular phase (low ALLO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Luteal phase (high ALLO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall smoking cessation outcomes in L phase
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall smoking cessation outcomes in F phase
Number of subjects: 84
Study: 20236148

Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-TME procedure
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: TME with radiosensitizing chemotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-TME with intra-operative radiotherapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (TME and non-TME)
Number of subjects: 124
Study: 18971535

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of SBP < 140 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of SBP > 150 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of DBP > 85 mmHg
Number of subjects: 0
Study: 17377092

Group type: EXPERIMENTAL
Intervention: Laser-assisted drug delivery at 2.0 J/cm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser-assisted drug delivery at 3.5 J/cm2
Number of subjects: 0
Study: 14742768

Group type: EXPERIMENTAL
Intervention: β-blockers as secondary prevention of MI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose β-blockers with slow titration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers in post-MI diabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower oral starting doses of β-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardioselective β-blockers and albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers in patients with peripheral arterial disease
Number of subjects: 0
Study: 11299089

Group type: EXPERIMENTAL
Intervention: Healthy diet (MDQI score)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Poor diet (MDQI score)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Wine drinking status
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Demographics associated with healthy diet
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Demographics associated with poor diet
Number of subjects: 964
Study: 9393379

Group type: EXPERIMENTAL
Intervention: Immediate zidovudine therapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 338
Study: 7649758

Group type: EXPERIMENTAL
Intervention: Self-help nursing intervention (9-page, 14-step workbook)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 3315611

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 65
Study: 31999360

Group type: EXPERIMENTAL
Intervention: Direct questioning
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Unmatched Count Technique (UCT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lone-actor terrorists
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: General population sample
Number of subjects: 125
Study: 31587813

Group type: EXPERIMENTAL
Intervention: Mobile management (MM) group received mobile health care services, including tailored mobile coaching.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional management (CM) group received conventional GDM management and could freely use the mobile health care application.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mobile management (MM) group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional management (CM) group
Number of subjects: 21
Study: 27295716

Group type: EXPERIMENTAL
Intervention: Neuromuscular fitted dental splint
Number of subjects: 23

Group type: COMPARATOR
Intervention: Habitual verticalized dental splint
Number of subjects: 23

Group type: COMPARATOR
Intervention: No splint condition
Number of subjects: 23
Study: 26098853

Group type: EXPERIMENTAL
Intervention: Game-Based Breathing Exercise (GBE) for 25 minutes a day, 3 days a week, during a 5 week period
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (conventional stroke rehabilitation program)
Number of subjects: 38
Study: 24871963

Group type: EXPERIMENTAL
Intervention: Equation for estimating the disposition index (DI) based on metabolic syndrome components.
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Equation based on demographic data and measurements of metabolic syndrome components.
Number of subjects: 167
Study: 21224324

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 116429

Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 116429

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 116429

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 116429

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 116429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116429
Study: 19413903

Group type: EXPERIMENTAL
Intervention: Stent treatment for coronary disease
Number of subjects: 132
Study: 17550444

Group type: EXPERIMENTAL
Intervention: Sodium hydroxide
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Phenol
Number of subjects: 46
Study: 15128052

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 372
Study: 11461053

Group type: EXPERIMENTAL
Intervention: Elite climbers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Recreational climbers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-climbers
Number of subjects: 30
Study: 9777765

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/d
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553
Study: 7886753

Group type: EXPERIMENTAL
Intervention: TALC Direct Recording Scale used by illiterate mothers for growth monitoring
Number of subjects: 0
Study: 3587722

Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thyrotropin Releasing Hormone (TRH)
Number of subjects: 56
Study: 30380162

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Anti-hepatitis B virus core antibody (anti-HBc)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: AAF index (combined AST, anti-HBc, and LSM)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Noninvasive models (23 models)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Liver biopsy avoidance
Number of subjects: 452
Study: 29105635

Group type: EXPERIMENTAL
Intervention: Unani medicine Renax
Number of subjects: 50

Group type: COMPARATOR
Intervention: Allopathic medicine (Spironolactone + Furosemide)
Number of subjects: 50
Study: 25559166

Group type: EXPERIMENTAL
Intervention: Medicare's nonpayment policy
Number of subjects: 1381
Study: 22907732

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Single‐marker analysis
Number of subjects: 112
Study: 21185559

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate mouth wash second hourly (Group B)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% aqueous oral rinse and second hourly irrigations with sterile water (Group C)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sterile water oral rinse second hourly (Group A)
Number of subjects: 109
Study: 19910812

Group type: EXPERIMENTAL
Intervention: Dynamic stretching followed by 8 front squats + 20% body mass (DSR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 20
Study: 17304660

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd
Number of subjects: 7111

Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg tid
Number of subjects: 7111
Study: 15045469

Group type: EXPERIMENTAL
Intervention: High-resolution MR imaging using a microscopy surface coil
Number of subjects: 18
Study: 11214952

Group type: EXPERIMENTAL
Intervention: GnRH agonist (depot leuprolide 3.75 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Finasteride (5 mg)
Number of subjects: 60
Study: 9200359

Group type: EXPERIMENTAL
Intervention: Lower fat intake
Number of subjects: 663
Study: 1336675

Group type: EXPERIMENTAL
Intervention: Sumatriptan (3 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study: 3515922

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 31003647

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercises
Number of subjects: 107

Group type: COMPARATOR
Intervention: Traditional physical exercises (Control)
Number of subjects: 107
Study: 28111997

Group type: EXPERIMENTAL
Intervention: Elastic bandage (EB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-standardised tape (NST)
Number of subjects: 28
Study: 27588943

Group type: EXPERIMENTAL
Intervention: 2-L PEG and Ascorbic Acid (Asc)
Number of subjects: 187

Group type: COMPARATOR
Intervention: 1-L PEG, Ascorbic Acid (Asc) and 20 mg Bisacodyl (Bis)
Number of subjects: 187
Study: 24856055

Group type: EXPERIMENTAL
Intervention: Isoflavone vaginal gel 4% (1g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 22414289

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 704

Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 704
Study: 20399613

Group type: EXPERIMENTAL
Intervention: UCSD Performance‐Based Skills Assessment (UPSA)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Brief UPSA
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment battery (NP)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: SSPA
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: UPSA
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: NP assessment
Number of subjects: 463

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: UPSA and NP
Number of subjects: 463
Study: 18175998

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 32
Study: 15616226

Group type: EXPERIMENTAL
Intervention: Glargine insulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultralente insulin
Number of subjects: 22
Study: 12620086

Group type: EXPERIMENTAL
Intervention: Interferential currents (IFC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham electrotherapy
Number of subjects: 30
Study: 10722763

Group type: EXPERIMENTAL
Intervention: Intravenous montelukast (7 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8623957

Group type: EXPERIMENTAL
Intervention: Desflurane with ondansetron (4 mg IV)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Desflurane only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane with ondansetron
Number of subjects: 90
Study: 1564466

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual postoperative analgesic treatment (diclofenac sodium twice daily for 5-10 days)
Number of subjects: 24
Study: 3908111

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31203158

Group type: EXPERIMENTAL
Intervention: Durable-polymer Resolute Onyx DES
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Polymer-free Biosensors BioFreedom DES
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both groups (Resolute Onyx and BioFreedom)
Number of subjects: 2000
Study: 29733464

Group type: EXPERIMENTAL
Intervention: IV Lacosamide (LCM) 400mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: IV Fosphenytoin (fPHT) 20mg phenytoin equivalents/kg
Number of subjects: 74

Group type: COMPARATOR
Intervention: LCM vs fPHT
Number of subjects: 74

Group type: COMPARATOR
Intervention: LCM and fPHT
Number of subjects: 74
Study: 25962813

Group type: EXPERIMENTAL
Intervention: Transforaminal steroid injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural steroid injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Caudal steroid injection
Number of subjects: 90
Study: 23828834

Group type: EXPERIMENTAL
Intervention: Modified Constraint-induced aphasia therapy (CIAT), 3 hours per day for a total of 30 hours of treatment.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional aphasia therapy, 3 hours per day for a total of 30 hours of treatment.
Number of subjects: 100
Study: 22315331

Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg kg(‐1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: neostigmine 50 μg kg(‐1)/glycopyrrolate 10 μg kg(‐1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: sugammadex
Number of subjects: 48

Group type: COMPARATOR
Intervention: neostigmine
Number of subjects: 48
Study: 20602109

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 36
Study: 18043345

Group type: EXPERIMENTAL
Intervention: Contrast material with iodine concentration of 370 mg/mL (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Contrast material with iodine concentration of 300 mg/mL (Group A)
Number of subjects: 80
Study: 16292115

Group type: EXPERIMENTAL
Intervention: Child-Parent Psychotherapy (CPP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Case management plus treatment as usual
Number of subjects: 75
Study: 15332747

Group type: EXPERIMENTAL
Intervention: Reduced antenatal care protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous maternity care by midwives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-quality reduced protocol by competent midwives
Number of subjects: 0
Study: 9137182

Group type: EXPERIMENTAL
Intervention: Open Bankart procedure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Arthroscopic procedure
Number of subjects: 34
Study: 7960983

Group type: EXPERIMENTAL
Intervention: 8 Gy to the lungs
Number of subjects: 85

Group type: COMPARATOR
Intervention: 6 Gy to the lungs
Number of subjects: 85
Study: 3235833

Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene) + methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene) + methyldopa (considering all cardiovascular events)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2144420

Group type: COMPARATOR
Intervention: Triglycerides (1.68/0.72 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Free fatty acids (1.35/1.065 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethyl esters (1.86/1.27 g)
Number of subjects: 8
Study: 788738

Group type: EXPERIMENTAL
Intervention: Inhaled salmefamol, 100 mug and 200 mug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol, 200 mug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30963410

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/day for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29768111

Group type: EXPERIMENTAL
Intervention: Right lateral position for 6 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine position for 6 hours
Number of subjects: 60
Study: 28290065

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Anticipated stress (previous night or morning)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 79
Study: 25826644

Group type: EXPERIMENTAL
Intervention: 1.0 mg (0.04 mL of 25 mg/mL) subconjunctival bevacizumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.04 mL of balanced salt solution
Number of subjects: 58
Study: 23249535

Group type: EXPERIMENTAL
Intervention: True moxibustion at point BL67 plus usual care
Number of subjects: 406

Group type: COMPARATOR
Intervention: Moxibustion at SP1 (sham moxibustion) plus usual care
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 406
Study: 21729164

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus ALA-PDT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cryotherapy plus placebo-PDT
Number of subjects: 80
Study: 19786776

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study: 16882269

Group type: EXPERIMENTAL
Intervention: Ruptured tubal ectopic pregnancy (REP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Unruptured tubal ectopic pregnancy (UREP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal intrauterine pregnancy (NIUP)
Number of subjects: 130
Study: 15197019

Group type: EXPERIMENTAL
Intervention: Care manager offered education, problem-solving treatment, or support for antidepressant management
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 11258636

Group type: EXPERIMENTAL
Intervention: Autonomic dysreflexia (ST2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No autonomic dysreflexia (ST1)
Number of subjects: 6
Study: 9224457

Group type: EXPERIMENTAL
Intervention: Conventional PMMA IOLs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surface‐passivated PMMA IOLs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heparin‐surface modified PMMA IOLs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Poly‐HEMA hydrogel IOLs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 50
Study: 8357782

Group type: EXPERIMENTAL
Intervention: 20 mg of quinapril once daily
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 1740
Study: 3122717

Group type: EXPERIMENTAL
Intervention: Astemizole (30 mg daily for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 31368861

Group type: EXPERIMENTAL
Intervention: ONIRO supplementation
Number of subjects: 70
Study: 30030321

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS) intervention
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Food-based (FB) intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 7
Study: 27497359

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents (BP‐SES)
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Durable polymer everolimus‐eluting stents (DP‐EES)
Number of subjects: 2041
Study: 24771603

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 513
Study: 22811447

Group type: EXPERIMENTAL
Intervention: Ten weeks of home-based occupational therapy according to the Dutch guidelines of occupational therapy in Parkinson's disease
Number of subjects: 43

Group type: COMPARATOR
Intervention: No occupational therapy
Number of subjects: 43